|
|

Title: Complex containing biologically assimilable
orthosilicic acid, which is under solid form, stable and concentrated, and
a process for preparation of said complex
United States Patent: 6,335,457
Inventors: Seguin; Marie-Christine (Monaco, MC); Gueyne; Jean
(Monaco, MC)
Assignee: Exsymol S.A.M. (Monaco, MC)
Appl. No.: 686882
Filed: October 12, 2000
Foreign Application Priority Data: Oct 15, 1999[FR] (99
13062)
Abstract
The invention concerns a complex containing biologically assimilable
orthosilicic acid and a process of preparation of said complex. In this
complex, orthosilicic acid is complexed with a polypeptide and the complex
is under solid, stable and concentrated form. The present invention also
concerns cosmetic or therapeutic compositions, and a nutritional
supplement containing said complex.
Description of the Invention
The present invention concerns a complex containing
biologically assimilable orthosilicic acid, which is under solid form,
stable and concentrated, and a process of preparation of said complex.
Silicon is an essential element for life. It has both a structural role
being a constituent of the proteins-glycosaminoglycanes complexes found in
the connective tissue's matrix, and a metabolic role on growth and
osteogenesis (silicon favours the process of mineralisation of the bone).
Thus, silicon is compulsory for a normal development of bones and
connective tissue.
It was also shown that silicon under the form of orthosilicic acid Si(OH)4
has a high affinity for Al3+ ions and enhances their
elimination. Thus, it could act against the toxic effects of aluminium on
bones and brain, especially in neurologic degenerative diseases such as
Alzheimer's disease.
These data suggest that a punctual supply in silicon can be very helpful,
during the growing period for instance, or in particular pathologies.
Nevertheless, it is also important to prevent silicon deficiency,: several
studies performed on human showed that silicon decreases with aging in
skin and arteries walls, essentially because of the decrease of
gastro-intestinal absorption of silicon in the course of time.
The main problem with silicon metabolism arises from the difficulty of its
assimilation. Although silicon is a very abundant element, it naturally
occurs under the form of minerals insoluble in water (crystalline oxides (silicas
and silicates) or amorphous (clays, opals, . . . )), which do not
represent a source of assimilable silicon for the organism.
Likewise, silicon as it naturally occurs in our food, i.e. essentially
under the form of aluminosilicates or silica, is very slightly assimilable.
The actual techniques of purification and refining of vegetable products
(dietary cereals and fibres are the main source of silicon), which tend to
eliminate the parts rich in silicon (the husks), have still reduced this
supply.
It seems now admitted that a biologically active form of silicon must be
hydrosoluble, and that the solubility depends on the amount of free OH
groups (silanol functions) on the silicon atom.
In blood and extravascular liquids, the silicon is physiologically present
under hydrated form of orthosilicic acid (Si(OH)4), non
dissociated at the pH of the organism, and almost completely in its free
form.
Moreover, studies have shown that only monomeric or oligomeric (very
slightly polimerized) orthosilicic acid is able to pass the intestinal
barrier (P. Creach, J. Adrian, Med. et Nut. 1990, 26(2), 73-90).
The presence on the silicon atom of free OH groups is closely linked to
its biological role. Indeed, these functions can make covalent or hydrogen
bonds with amides, water, alcohols, ketones, esters, . . . .
Thus, in biological media, bonds with the membrane's phospholipids,
proteins, glycosaminoglycanes and polysaccharides can be formed.
So it is necessary to conceive a silicon supply in which silicon is under
the form of silicic acid or a form as similar as possible.
Monomeric orthosilicic acid in solution is relatively stable until a
concentration of about 10-4 Mol.l-1 ; but, when the
concentration increases, the Si(OH)4 molecules associate to
make oligomers and polymers of orthosilicic acid (formation of siloxane
bonds Si--O--Si) to finally make colloidal solutions or silica gels that
are weakly soluble or insoluble in water, and which silicon
biodisponibility is very weak.
The supply of orthosilicic acid under the form of very diluted stable
solutions do not comply with a daily supplementation in silicon and also
make impossible its incorporation, in sufficiently high amounts, in
nutrients or dietetic, cosmetic or therapeutic compositions.
The already available sources of biologically active and concentrated
silicon are organosilicic compounds presenting several free hydroxyl
groups, that can be found under the form of solutions or under solid form
(EP- 0 289 366 and FR 2 761 074 patents).
Besides, more concentrated solutions of orthosilicic acid are available,
in which orthosilicic acid is stabilized by a very acid pH that
counteracts the polymerization by hydrolyzing the siloxane bonds Si--O--Si
(patent JP 58176115).
The patent WO 95/21124 also proposes concentrated preparations of
orthosilicic acid stabilized by a stabilizer. A complex between
orthosilicic acid and choline in solution is made, but a good stability
can not be obtained without maintaining an acid pH.
Such acid solutions do not provide an optimal assimilation because during
ingestion, the pH conditions are not maintained (physiological pH). An
important part of the orthosilicic acid polymerizes before being
assimilated.
In the scope of a medical study, a topical application of colloidal
silicic acid was combined with an oral intake in order to improve aged
skin, fragile hair and brittle nails (Lassus A., Journal of International
Medical Research 1993, 21, 209-215). However, the biodisponibility of this
form is weak because of the presence of many siloxane bonds.
This is why a purpose of the invention is proposing a form of orthosilicic
acid which is assimilable, concentrated and stable.
Moreover, to be orally assimilable, orthosilicic acid has to be soluble
and chemically stable at the different physiological pH that is to say in
acidic, neutral or slightly alkaline medium Thus an other aim of the
invention is obtaining a form of orthosilicic acid which is stable at
these different pH.
Lastly, an other purpose was to obtain a solid form which can be
incorporated in dietetic, cosmetic or therapeutic compositions, and in
nutritional supplements, under non aqueous forms: capsules, granules or
tablets for oral administration.
These objectives can be reached by complexing orthosilicic acid with a
polypeptide which acts as a stabilizer by forming hydrogen bonds with
orthosilicic acid. This prevents the formation of siloxane bonds and
orthosilicic acid polymerisation.
A stable solid form (powder) of orthosilicic acid is thus obtained which
is, after ingestion, solubilized in biological fluids to release a soluble
form of assimilable and biologically active orthosilicic acid (monomeric
or oligomeric).
Notwithstanding the excellent stability of the concentrated solid form, an
important characteristic of the invention is its ability to remain stable
during its transit in the gastrointestinal tractus, and this despite the
existence of different physiological pH favouring its polymerisation.
This can be explained by the particularly strong interaction existing
between the silicon and the polypeptide. When dissolving, the complex
between the polypeptidic chain and the hydroxylic functions carried by the
silicon atom remains; the cohesion of the complex is linked to the
formation of a group of weak bonds (hydrogen bonds) and probably to the
structural organisation of the polypeptidic chain.
It is to be noted that in the prospect of preparing a sustained-release
form, some peptides having a pharmacological activity have been associated
to natural minerals containing silicon or to synthetic minerals made of
silicic acid (patent No. BE 778.239). The common characteristic of all
these silicon compounds is the formation of a colloidal suspension
suitable as a support for the peptides; it is clear that the technical
problem treated in this patent has no connection with the present
invention.
The subject of the present invention is proposing a complex containing
biologically assimilable orthosilicic acid in which orthosilicic acid is
complexed with a polypeptide and is under solid, stable and concentrated
form.
The subject of the present invention is also to provide a process of
preparation of the said complex containing orthosilicic acid, comprising
the following steps:
the polypeptide is dissolved in 1 volume of distilled water
the pH is adjusted between 2 and 4
in a proportion comprised between 1/4 and 1 volume, an alcohol soluble in
water, preferably ethanol, is added under stirring,
a hydrolyzable precursor of orthosilicic acid, preferably a
tetraalkoxysilane, is added dropwise
the mixture is maintained under stirring until complete hydrolysis of the
precursor
alcohol and water are evaporated.
An orthosilicic acid-polypeptide complex is thus obtained, which is under
the form of a powdery, slightly colored solid, having a silicon content up
to 10%. Preferably, the silicon content is comprised between 1 and 5%.
Following an advantageous embodiment of the invention, the polypeptide is
a hydrolysate of proteins from animal or vegetable origin.
In fact, it was established that polypeptides obtained after strong
hydrolysis were the most appropriate for the realisation of the purposes
of the invention.
The polypeptides of high molecular weight, and particularly certain
proteins, appeared to be bad stabilizers. This may be explained by the
tertiary structure of these proteins which is not suitable with a
stabilizing arrangement with orthosilicic acid.
Following a preferred embodiment of the invention, the polypeptide is a
collagen hydrolysate, such as porc or fish collagen.
In fact, among proteins hydrolysates from animal origin, the collagen
hydrolysate is particularly suitable since collagen has a structure that
favours the formation of a complex with orthosilicic acid.
Besides, silicon is strongly associated to collagen in vivo (Carlisle EM,
The Science of Total Environment, 1988, vol.73, 95-106).
Lastly, an other aim of the present invention is to propose cosmetic or
therapeutic compositions and also a nutritional supplement containing, in
association with any suitable excipient, such a complex.
Among the numerous uses of these nutritional compositions and supplements
can be mentioned: silicon deficiencies, need of an important intake for
pregnant woman, growing child, or elderly people for whom both silicon
assimilation ability and tissular binding are reduced, for regeneration
and strengthening of skin, hair, nails or prevention and treatment of
diseases such as osteoporosis or atherosclerosis.
Claim 1 of 6 Claims
What is claimed is:
1. Complex containing biologically assimilable orthosilicic acid, wherein
orthosilicic acid is complexed with a polypeptide and under solid, stable
and concentrated form.
____________________________________________
If you want to learn more
about this patent, please go directly to the U.S.
Patent and Trademark Office Web site to access the full
patent.
|